Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Mee...

Lead Product(s): EDP1503,Pembrolizumab

Therapeutic Area: Oncology Product Name: EDP1503

Highest Development Status: Phase I/ Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 01, 2020

Details:

An overall response rate (ORR) of 25% (2/8) and a disease control rate of 37.5% (3/8) were observed across all TNBC subjects receiving high dose EDP1503.

Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evelo Biosciences Announces Proposed Public Offering of Common Stock

Lead Product(s): EDP1815

Therapeutic Area: Infections and Infectious Diseases Product Name: EDP1815

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Morgan Stanley

Deal Size: $46.0 million Upfront Cash: Undisclosed

Deal Type: Public Offering June 24, 2020

Details:

The net proceeds from the offering will be used to adavnace existing pipeline including, EDP1815, continue the clinical development of EDP1503, and development activities for additional product candidates, including EDP1867 and EDP2939.

Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evelo Biosciences announces EDP1815 to advance into phase 2/3 TACTIC-E COVID-19 trial

Lead Product(s): EDP1815,Ambrisentan,Dapagliflozin

Therapeutic Area: Infections and Infectious Diseases Product Name: EDP1815

Highest Development Status: Phase II/ Phase III Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 22, 2020

Details:

EDP1815 will be included in the TACTIC-E clinical trial. The trial will evaluate the safety and efficacy of certain experimental therapies in the prevention and treatment of life-threatening complications associated with COVID-19 in hospitalized patients.

Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Flagship-Backed Evelo Biosciences Joins Covid-19 Hunt With Proposal for Bacteria Trial

Lead Product(s): EDP1815

Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed

Highest Development Status: Phase II Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 07, 2020

Details:

Phase 2 clinical study is evaluating the safety and efficacy of EDP1815 for the treatment of hospitalized patients with newly diagnosed COVID-19.

Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evelo Biosciences Announces Biomarker Data Showing EDP1815

Lead Product(s): EDP1815

Therapeutic Area: Immunology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable March 02, 2020

Details:

Interim data from individuals in the ongoing Phase 1b clinical trial showed marked activity on multiple individual systemic markers of inflammation.

Evelo Biosciences

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

United States

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline t...

Lead Product(s): EDP1815

Therapeutic Area: Dermatology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable January 10, 2020

Details:

Evelo has agreed upon the design of the EDP1815 Phase 2 clinical trial with global regulatory agencies. The dose ranging study will evaluate three doses of EDP1815 versus placebo in 180 individuals.

Find

Find Clinical Drug Pipeline Developments & Deals by Evelo Biosciences

Pipeline Prospector Find Drug Development Pipeline & Deal Updates

Companies By Therapeutic Area

Development Status

Evelo Biosciences

Evelo Biosciences to Present Clinical Data from Phase 1/2 Trial of EDP1503 at the ESMO World Congress on Gastrointestinal Cancer Virtual Mee...

Evelo Biosciences

Evelo Biosciences Announces Proposed Public Offering of Common Stock

Evelo Biosciences

Evelo Biosciences announces EDP1815 to advance into phase 2/3 TACTIC-E COVID-19 trial

Evelo Biosciences

Flagship-Backed Evelo Biosciences Joins Covid-19 Hunt With Proposal for Bacteria Trial

Evelo Biosciences

Evelo Biosciences Announces Biomarker Data Showing EDP1815

Evelo Biosciences

Evelo Provides Update on Recent Positive EDP1815 Regulatory Interactions on Phase 2 Trial Design Resulting in Shorter Development Timeline t...